Results 191 to 200 of about 2,204,237 (310)

Inflammation and Cancer: Molecular Mechanisms and Therapeutic Targets

MedComm, Volume 7, Issue 2, February 2026.
Chronic inflammation fuels tumorigenesis via “internal drivers” and “external attractions.” Targeting these core mechanisms with combined therapies/novel deliveries enables precise, potent anti‐inflammatory–antitumor treatment. ABSTRACT Inflammation is a core pathological factor regulating tumor initiation, progression, and therapeutic resistance, and ...
Xiaodie Liu, Ziyuan Wang, Huirong Zhu, Yicun Han, Qing Ji   +4 more
wiley   +1 more source

Progress in RNA‐Targeted Therapeutics for Human Diseases

MedComm, Volume 7, Issue 2, February 2026.
RNA‐targeted therapies are revolutionizing molecular medicine by transitioning from a “protein‐centric” focus to an “RNA‐regulatory network” approach. Leveraging RNA's diverse roles in gene regulation, signaling, and epigenetic modifications, advanced platforms such as ASOs, siRNA, miRNA, mRNA, aptamers, shRNA, and CRISPR/Cas systems are enabling ...
Wangzheqi Zhang, Aimin Jiang, Bin‐Kui Jia, Yuming Jin, Yinghu Chen, Zhaoyu Li, Yan Liao, Haoling Zhang, Zhiheng Lin, Xiao Fang, Linhui Wang   +10 more
wiley   +1 more source

A Highly Sensitive Silicon Nanowire Array Field Effect Transistor Biosensor for Detecting HBV-DNA and AFP. [PDF]

Sensors (Basel)
Sun P, Liu M, Zhang Y, Liu C, Yang X.
europepmc   +1 more source

A small molecule iCDM-34 identified by in silico screening suppresses HBV DNA through activation of aryl hydrocarbon receptor. [PDF]

Cell Death Discov, 2023
Furutani Y, Hirano Y, Toguchi M, Higuchi S, Qin XY, Yanaka K, Sato-Shiozaki Y, Takahashi N, Sakai M, Kongpracha P, Suzuki T, Dohmae N, Kukimoto-Niino M, Shirouzu M, Nagamori S, Suzuki H, Kobayashi K, Masaki T, Koyama H, Sekiba K, Otsuka M, Koike K, Kohara M, Kojima S, Kakeya H, Matsuura T.   +25 more
europepmc   +1 more source

Lamivudine Monotherapy-Based cART Is Efficacious for HBV Treatment in HIV/HBV Coinfection When Baseline HBV DNA <20,000 IU/mL

Journal of Acquired Immune Deficiency Syndromes, 2016
Yijia Li, Jing Xie, Yang Han, Huan-ling Wang, Ting Zhu, Nidan Wang, W. Lv, F. guo, Z. Qiu, Yan-ling Li, Shanshan Du, Xiao-jing Song, C. Thio, Taisheng Li   +13 more
semanticscholar   +1 more source

IKAROS Associated Immunodeficiency and Thrombotic Thrombocytopenic Purpura

Pediatric Blood &Cancer, Volume 73, Issue 2, February 2026.
ABSTRACT Pathogenic variants in IKZF1 (IKAROS) are linked to immunodeficiency, malignancy, and immune dysregulation. We describe a family with a rare IKZF1 variant presenting with humoral immunodeficiency and thrombotic thrombocytopenic purpura (TTP). A non‐consanguineous family was clinically monitored; clinical, immunological, and genetic data (exome
Ilia Spivak, Daniella Magen, Karin Weiss, Tamar Paperna, Suhair Hanna, Amos Etzioni, Adi Miller‐Barmak, Yonatan Butbul Aviel   +7 more
wiley   +1 more source

A single-cell digital PCR method tailored for quantification of HBV DNA positive cells in liver biopsy tissues. [PDF]

J Transl Med
Li J, Li H, Zhang X, Liu X, Zhou Z, Wei J, Zhao R, Zhou TC, Zhang Z, Li C.   +9 more
europepmc   +1 more source

Monitoring of Hepatitis B Virus (HBV) DNA and Risk of HBV Reactivation in B-Cell Lymphoma: A Prospective Observational Study.

Clinical Infectious Diseases, 2015
S. Kusumoto, Yasuhito Tanaka, R. Suzuki, Takashi Watanabe, M. Nakata, H. Takasaki, N. Fukushima, T. Fukushima, Y. Moriuchi, K. Itoh, K. Nosaka, I. Choi, M. Sawa, R. Okamoto, H. Tsujimura, T. Uchida, Sachiko Suzuki, M. Okamoto, Tsutomu Takahashi, I. Sugiura, Y. Onishi, M. Kohri, S. Yoshida, R. Sakai, M. Kojima, Hiroyuki Takahashi, A. Tomita, D. Maruyama, Y. Atsuta, E. Tanaka, Takayo Suzuki, T. Kinoshita, M. Ogura, M. Mizokami, R. Ueda   +34 more
semanticscholar   +1 more source

A Systematic Review and Model‐Based Meta‐Analysis of Pegylated‐Interferon‐α‐Induced HBsAg Loss in Chronic Hepatitis B Virus Infection

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 2, February 2026.
ABSTRACT Pegylated‐interferon‐α (Peg‐IFNα) is a treatment option for chronic hepatitis B virus (HBV) infection. To quantify treatment response variability, we conducted a model‐based meta‐analysis (MBMA) of hepatitis B surface antigen (HBsAg) loss, defined as a binary outcome based on HBsAg levels falling below the limit of detection, with Peg‐IFNα ...
Nathan J. Hanan, Matthew L. Zierhut, Ahmed Nader, Anadi Mahajan, Amandeep Kaur, Krishna Kumar, Susan A. Dixon, Joyeta Das, Mindy Magee, Dickens Theodore, Vera Gielen   +10 more
wiley   +1 more source

Risk of hepatitis B virus reactivation in the treatment of HBsAg and HBV DNA double-negative lymphoma patients. [PDF]

PLoS One
Chen L, Lu Z, Zhang X, Lai J, Huang G, Zheng Y.   +5 more
europepmc   +1 more source